Clinical Trial for Chronic Lymphocytic Leukemia (CLL)
The research study sets out to learn about changes in the genetic makeup of CLL during the early phase of treatment with venetoclax. The initial phase of venetoclax therapy can be medically and logistically challenging. Patients will receive expert medical care at the National Institutes of Health.
Partner in Research
The NIH is looking for patients with CLL that has progressed despite treatment or were intolerant to therapy.
Treatment at NIH
Patients are provided the novel agent venetoclax for roughly five weeks. There is no charge for study-related tests, procedures or medications at NIH. Patients have NIH follow-up every six months. Compensation for travel and lodging is provided.
Continue at Local Providers
After the initial phase of venetoclax is complete, patients transition to the care of their local hematologist/oncologist to receive venetoclax through their provider.
Location: The NIH Clinical Center, America's Research Hospital, is located in Bethesda, MD, on the Metro red line (Medical Center stop). Parking is available.
For more information:
NIH Clinical Center Office of Patient Recruitment
1-800-411-1222 (refer to study # 19-H-0111)
(TTY users dial 7-1-1)
Se habla español
Email: ccopr@nih.gov
Or go online:
https://go.usa.gov/xyrqb
Department of Health and Human Services
National Institutes of Health Clinical Center
National Heart, Lung and Blood Institute